Metamizol-Sf (Metamizole Sodium Monohydrate)

Metamizole sodium works by non‑selectively inhibiting cyclooxygenase enzymes, which lowers prostaglandin production. This reduction diminishes peripheral pain signaling and resets the hypothalamic temperature set‑point, while central mechanisms add to its analgesic and spasmolytic actions.

The appropriate dose of Metamizol‑Sf is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal or hepatic function. Dosage regimens are individualized and should follow local prescribing guidelines.

Safety data for metamizole sodium in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit outweighs any possible risk to the mother or infant, and under medical supervision.

To order Metamizol‑Sf, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metamizole‑Sf belongs to the pyrazolone class, offering both analgesic and antipyretic activity. Compared with NSAIDs, it has a lower risk of gastrointestinal irritation but carries a rare risk of severe blood dyscrasias. Unlike opioids, it does not cause respiratory depression, making it a useful alternative for certain pain scenarios.

Metamizol‑Sf should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and potency.

Metamizol‑Sf is supplied as a sterile injectable solution and can be given either intramuscularly or intravenously by a qualified healthcare professional. The route and rate of administration are determined by the prescriber according to the clinical situation.

The most serious risks include agranulocytosis and aplastic anemia, both of which are rare but potentially life‑threatening blood disorders. Early signs such as unexplained fever, sore throat, or infections should prompt immediate medical evaluation.

Metamizol‑Sf is contraindicated in patients with a known hypersensitivity to metamizole or other pyrazolones, those with a history of agranulocytosis or severe bone‑marrow suppression, and individuals with severe hepatic or renal impairment unless specifically directed by a physician.